Aldeyra Therapeutics, Inc. (ALDX): Product News News

ALDX – Announces that the FDA has granted Aldeyra’s novel compound ADX-102 orphan drug designation for the treatment of congenital ichthyosis.


Key Facts Surrounding This News Item


  • ALDX had a POWR Rating of D (Sell) coming into today.
  • ALDX was 4.97% above its 10-Day Moving Average coming into today.
  • ALDX was 3.75% above its 20-Day Moving Average coming into today.
  • ALDX was 3.76% above its 50-Day Moving Average coming into today.
  • ALDX was 1.63% above its 100-Day Moving Average coming into today.
  • ALDX was -8.35% below its 200-Day Moving Average coming into today.
  • ALDX had returned -2.80% year-to-date leading up to today’s news, versus a +4.89% return from the benchmark S&P 500 during the same period.

More Info About Aldeyra Therapeutics, Inc. (ALDX)


Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts. View our full ALDX ticker page with ratings, news, and more.

ALDX at a Glance

ALDX Current POWR Rating™
Overall POWR Rating™
ALDX Current Price $4.30 1.15%
More ALDX Ratings, Data, and News

ALDX Price Reaction

The day of this event (Apr. 20, 2017)
ALDX Closing Price$4.35 16.35%
ALDX Volume1,832,900
4,223.40% from avg
Leading up to this event
ALDX 1-mo return0.95%
After this event
ALDX 1-day return18.18%
ALDX 3-day return20.93%
ALDX 5-day return19.54%

ALDX Price Chart

More Aldeyra Therapeutics, Inc. (ALDX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ALDX News
Page generated in 0.9402 seconds.